3 results match your criteria: "University of Melbourne-Peter Doherty Institute for Infection and Immunity[Affiliation]"
Effect of pneumococcal conjugate vaccination on pneumococcal carriage in hospitalised children aged 2-59 months in Mongolia: an active pneumonia surveillance programme.
Lancet Microbe
December 2024
Infection, Immunity and Global Health, Murdoch Children's Research Institute, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia; Department of Microbiology and Immunology, University of Melbourne-Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Background: Data on changes in pneumococcal serotypes in hospitalised children following the introduction of the pneumococcal conjugate vaccine (PCV) in low-income and middle-income countries are scarce. In 2016, Mongolia introduced the 13-valent PCV (PCV13) into the national immunisation programme. We aimed to describe the trend and impact of PCV13 introduction on pneumococcal carriage in hospitalised children aged 2-59 months with pneumonia in Mongolia over a 6-year period.
View Article and Find Full Text PDFHousehold transmission investigation: Design, reporting and critical appraisal.
Influenza Other Respir Viruses
June 2023
Department of Infectious Diseases, The University of Melbourne Peter Doherty Institute for Infection and Immunity Melbourne Victoria Australia.
Background: Household transmission investigations (HHTIs) contribute timely epidemiologic knowledge in response to emerging pathogens. HHTIs conducted in the context of the COVID-19 pandemic in 2020-21 reported variable methodological approaches, producing epidemiological estimates that vary in meaning, precision and accuracy. Because specific tools to assist with the optimal design and critical appraisal of HHTIs are not available, the aggregation and pooling of inferences from HHTIs to inform policy and interventions may be challenging.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on developing an effective SARS-CoV-2 vaccine using a prefusion-stabilized spike protein, Sclamp, combined with the adjuvant MF59 'MF59C.1'.
- Researchers produced and screened a panel of recombinant Sclamp proteins, assessing their structure and effectiveness through various animal studies.
- The results showed that the Sclamp vaccine generates strong immune responses, effectively reduces viral loads, and protects against lung disease in animal models, while being suitable for large-scale manufacturing.